Phase 2b trial assessing KT-621 in atopic dermatitis (AD) patients
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs KT 621 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- 21 Jan 2025 New trial record
- 14 Jan 2025 According to Kymera Therapeutics media release, the company will initiate KT-621 Phase 2b clinical trial in AD in the fourth quarter of 2025